Tevogen Bio's (TVGN) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Tevogen Bio (NASDAQ:TVGN - Free Report) in a report published on Monday,Benzinga reports. The brokerage currently has a $10.00 price target on the stock.

Tevogen Bio Trading Down 1.8 %

Shares of NASDAQ:TVGN traded down $0.02 during trading on Monday, hitting $0.99. 282,139 shares of the company's stock traded hands, compared to its average volume of 5,049,411. Tevogen Bio has a 52 week low of $0.26 and a 52 week high of $3.09. The company has a 50-day moving average price of $1.13 and a 200-day moving average price of $1.31.

Insider Activity

In other Tevogen Bio news, insider Neal Flomenberg sold 70,384 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $1.09, for a total transaction of $76,718.56. Following the transaction, the insider now owns 3,898,828 shares of the company's stock, valued at $4,249,722.52. The trade was a 1.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 406,510 shares of company stock valued at $446,763 in the last quarter. Company insiders own 56.60% of the company's stock.

Hedge Funds Weigh In On Tevogen Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in shares of Tevogen Bio by 31.2% during the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock worth $465,000 after buying an additional 107,566 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Tevogen Bio in the 4th quarter valued at approximately $55,000. China Universal Asset Management Co. Ltd. acquired a new stake in Tevogen Bio in the fourth quarter valued at approximately $38,000. JPMorgan Chase & Co. grew its stake in shares of Tevogen Bio by 74.2% during the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock worth $40,000 after buying an additional 16,695 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Tevogen Bio by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock worth $122,000 after buying an additional 13,595 shares in the last quarter.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.